Detalhe da pesquisa
1.
Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies.
Blood
; 137(16): 2231-2242, 2021 04 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-33512413
2.
Effect of emicizumab prophylaxis on bone and joint health markers in people with haemophilia A without factor VIII inhibitors in the HAVEN 3 study.
Haemophilia
; 28(6): 1033-1043, 2022 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-35905294
3.
Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors.
N Engl J Med
; 379(9): 811-822, 2018 08 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-30157389
4.
A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors.
Blood
; 134(24): 2127-2138, 2019 12 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31697801
5.
The effect of emicizumab prophylaxis on long-term, self-reported physical health in persons with haemophilia A without factor VIII inhibitors in the HAVEN 3 and HAVEN 4 studies.
Haemophilia
; 27(5): 854-865, 2021 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-34171159
6.
Emicizumab Prophylaxis in Hemophilia A with Inhibitors.
N Engl J Med
; 377(9): 809-818, 2017 08 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-28691557
7.
Outcomes in children with hemophilia A with inhibitors: Results from a noninterventional study.
Pediatr Blood Cancer
; 67(10): e28474, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32776489
8.
Health-related quality of life and health status in persons with haemophilia A with inhibitors: A prospective, multicentre, non-interventional study (NIS).
Haemophilia
; 25(3): 382-391, 2019 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-31016855
9.
Bleeding events and safety outcomes in persons with haemophilia A with inhibitors: A prospective, multi-centre, non-interventional study.
Haemophilia
; 24(6): 921-929, 2018 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-30295389
10.
Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial.
Lancet Oncol
; 17(6): 811-821, 2016 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-27155741
11.
Emicizumab Prophylaxis in Hemophilia A with Inhibitors.
N Engl J Med
; 377(22): 2194-2195, 2017 11 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-29171814
12.
A Model-Based Framework to Inform the Dose Selection and Study Design of Emicizumab for Pediatric Patients With Hemophilia A.
J Clin Pharmacol
; 62(2): 232-244, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34545950
13.
Untreated bleeds in people with hemophilia A in a noninterventional study and intrapatient comparison after initiating emicizumab in HAVEN 1-3.
Res Pract Thromb Haemost
; 6(6): e12782, 2022 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-36171959
14.
Pharmacokinetics and Pharmacodynamics of Emicizumab in Persons with Hemophilia A with Factor VIII Inhibitors: HAVEN 1 Study.
Thromb Haemost
; 121(3): 351-360, 2021 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-33086400
15.
A phase 2 PK/PD study of andexanet alfa for reversal of rivaroxaban and edoxaban anticoagulation in healthy volunteers.
Blood Adv
; 4(4): 728-739, 2020 02 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-32092140
16.
Safety analysis of rFVIIa with emicizumab dosing in congenital hemophilia A with inhibitors: Experience from the HAVEN clinical program.
J Thromb Haemost
; 17(9): 1470-1477, 2019 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-31124272
17.
Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study.
Lancet Haematol
; 6(6): e295-e305, 2019 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-31003963
18.
A Pharmacometric Approach to Substitute for a Conventional Dose-Finding Study in Rare Diseases: Example of Phase III Dose Selection for Emicizumab in Hemophilia A.
Clin Pharmacokinet
; 57(9): 1123-1134, 2018 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-29214439
19.
First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors.
Clin Cancer Res
; 21(1): 77-86, 2015 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-25370471
20.
The endothelial-specific regulatory mutation, Mvwf1, is a common mouse founder allele.
Mamm Genome
; 19(1): 32-40, 2008 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-18188647